Dicerna expects to continue collaborating with Novo's rivals after potential acquisition

CEO at Dicerna Douglas Fambrough is fully anticipating that the US-based biotech company will live up to the obligations it has made to other companies, even in the case that the recently announced takeover bid by Novo Nordisk is a success, he tells MedWatch.

Photo: Mike Blake/Reuters/Ritzau Scanpix

Even if Novo Nordisk's takeover bid becomes a success, business will continue as usual when it comes to Dicerna's partnerships with Novo's rivals Eli Lilly and Boehringer Ingelheim, CEO at Dicerna Douglas Fambrough tells MedWatch.

This is at least what the CEO is expecting to happen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs